Novartis Past Earnings Performance

Past criteria checks 5/6

Novartis has been growing earnings at an average annual rate of 5.8%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been declining at an average rate of 0.07% per year. Novartis's return on equity is 22.9%, and it has net margins of 19.1%.

Key information

5.8%

Earnings growth rate

7.5%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	-0.07%
Return on equity	22.9%
Net Margin	19.1%
Next Earnings Update	18 Jul 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown
Beta

How Novartis makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:NVSE.F Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Mar 24	47,733	9,107	12,438	8,673
31 Dec 23	46,660	8,568	12,489	9,011
30 Sep 23	54,217	8,151	14,225	9,026
30 Jun 23	52,908	7,968	14,068	9,212
31 Mar 23	41,694	5,976	11,522	8,680
31 Dec 22	43,461	6,049	12,143	8,425
30 Sep 22	46,017	21,042	12,924	8,975
30 Jun 22	48,601	22,472	13,606	8,813
31 Mar 22	52,997	24,184	14,798	9,119
31 Dec 21	43,974	22,908	12,756	8,259
30 Sep 21	52,385	9,807	14,721	9,032
30 Jun 21	51,556	8,984	14,522	8,798
31 Mar 21	49,884	7,955	14,136	8,839
31 Dec 20	49,898	8,072	14,197	8,980
30 Sep 20	49,584	7,103	14,128	8,534
30 Jun 20	49,528	7,210	14,258	8,587
31 Mar 20	49,930	7,451	14,475	8,197
31 Dec 19	48,677	7,142	14,369	9,402
30 Sep 19	47,858	7,238	14,114	8,627
30 Jun 19	46,762	7,077	13,826	8,575
31 Mar 19	46,391	12,697	13,736	8,650
31 Dec 18	46,099	12,797	13,717	8,489
30 Sep 18	47,366	13,552	14,084	8,295
30 Jun 18	48,672	13,752	14,501	8,387
31 Mar 18	49,513	8,004	14,812	8,323
31 Dec 17	43,404	7,499	12,468	7,995
30 Sep 17	49,527	6,684	14,713	8,460
30 Jun 17	49,176	6,543	14,435	8,445
31 Mar 17	49,361	6,367	14,278	8,573
31 Dec 16	49,386	6,712	14,111	8,445
30 Sep 16	49,606	6,807	14,110	8,773
30 Jun 16	49,750	6,672	14,173	8,739
31 Mar 16	49,967	6,722	14,141	8,755
31 Dec 15	50,387	7,017	14,247	8,935
30 Sep 15	50,635	8,417	14,241	8,685
30 Jun 15	51,450	9,697	14,343	8,656
31 Mar 15	52,503	10,536	14,552	8,628
31 Dec 14	53,634	10,657	14,993	9,086
30 Sep 14	53,908	10,191	15,122	8,910
30 Jun 14	53,514	9,233	15,231	8,965
31 Mar 14	52,845	9,095	15,189	9,034
31 Dec 13	52,716	9,192	15,189	8,946
30 Sep 13	54,100	9,191	15,720	9,077
30 Jun 13	55,233	9,454	16,132	9,052

Quality Earnings: NVSE.F has a large one-off loss of $4.1B impacting its last 12 months of financial results to 31st March, 2024.

Growing Profit Margin: NVSE.F's current net profit margins (19.1%) are higher than last year (14.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NVSE.F's earnings have grown by 5.8% per year over the past 5 years.

Accelerating Growth: NVSE.F's earnings growth over the past year (52.4%) exceeds its 5-year average (5.8% per year).

Earnings vs Industry: NVSE.F earnings growth over the past year (52.4%) exceeded the Pharmaceuticals industry -6.8%.

Return on Equity

High ROE: NVSE.F's Return on Equity (22.9%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Novartis Past Earnings Performance

Past criteria checks 5/6

Key information

Recent past performance updates

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Recent updates

Novartis and Medicines for Malaria Venture Announce Positive Efficacy and Safety Data for A Novel Treatment for Babies

Novartis AG Revise Earnings Guidance for the Year 2024

Novartis' Intravenous Formulation of Cosentyx Impacting Prescriber Preferences in Psoriatic Arthritis Treatment, While Pending Launch of UCB’s Bimzelx Poised to Further Disrupt the Market

Novartis Presents Results from Pre-Specified Interim Analysis of the Phase III APPLAUSE-IgAN study of Fabhalta

Novartis Fabhalta Receives Positive CHMP Opinion as First Oral Monotherapy for Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Novartis AG (SWX:NOVN) acquired IFM Due, Inc. from IFM Therapeutics, LLC for approximately $840 million.

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Novartis AG Announces FDA Approves Xolair® (Omalizumab) as First and Only Medicine for Children and Adults with One or More Food Allergies

Novartis Reportedly in Lead to Acquire MorphoSys

Novartis AG Provides Earnings Guidance for the Year 2024

Novartis AG to Report Q1, 2024 Results on Apr 23, 2024

Novartis AG Presents Data from the Phase III NETTER-2 Trial

Novartis Pursuit of Cytokinetics Reportedly Cools

Novartis Reportedly in Advanced Talks to Buy Cytokinetics

Novartis AG Announces Positive Results from the Primary Analysis of ASC4FIRST

Novartis AG (SWX:NOVN) acquired SanReno Therapeutics from Pivotal bioVenture Partners China, Versant Venture Management, LLC, Samsara BioCapital LLC, Frazier Healthcare Partners managed by Frazier Management, L.L.C. and Frazier Life Sciences Management, LP.

Novartis Investigational Iptacopan Phase III Study Demonstrates Clinically Meaningful and Statistically Significant Proteinuria Reduction in Patients with C3 Glomerulopathy (C3G)

Latest Novartis Kisqali(R) Natalee Analysis Reinforces 25% Reduction in Risk of Recurrence Across Broad Population of Patients with Early Breast Cancer

Novartis Receives FDA Approval for Fabhalta (iptacopan) Offering Superior Hemoglobin Improvement in the Absence of Transfusions as the First Oral Monotherapy for Adults with PNH

Novartis AG to Report Q4, 2023 Results on Jan 31, 2024

Novartis Announces New Positive Data from the Phase III REMIX-1 and REMIX-2 Studies Investigating Remibrutinib

Novartis Announces US Food and Drug Administration Approves Cosentyx® to Treat Moderate to Severe Hidradenitis Suppurativa in Adults

Novartis Announces Positive Topline Results from the Interim Analysis of the Ongoing Pivotal Phase III ALIGN Study

Novartis AG Announces Impairment Charges for the Third Quarter of 2023

Novartis AG Raises Earnings Guidance for the Fiscal Year 2023

Novartis Kisqali Natalee Analysis Confirms Consistent Reduction in Risk of Recurrence Across Key Sub Groups of Patients with Early Breast Cancer

FDA Approves Novartis Cosentyx® as First Intravenous (Iv) Formulation Interleukin-17A Antagonist for Rheumatic Diseases

Novartis to Present New Oncology Data at ESMO 2023 Demonstrating Practice-Changing Innovation in Advanced Prostate and Early Breast Cancer

Novartis AG completed the Spin-Off of Sandoz Group AG (SWX:SDZ).

Bausch & Lomb Ireland completed the acquisition of ophthalmology assets of Novartis AG from Novartis AG for $2.5 billion.

Sandoz, Novartis Division, Receives European Commission Approval for Tyruko (Natalizumab), First and Only Biosimilar for Multiple Sclerosis in Europe

Novartis Radioligand Therapy Lutathera® Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival in First Line Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

Novartis AG Issues Voluntary Nationwide Recall of One Lot of Sandimmune Oral Solution (cyclosporine oral solution, USP), 100 mg/mL due to Crystallization

Novartis AG Announces Executive Changes

Novartis Presents New Long-Term Leqvio (Inclisiran) Data Demonstrating Consistent Efficacy and Safety Beyond Six Years

Sandoz Announces Positive Results from Mylight Phase III Study for Biosimilar Aflibercept

Novartis AG (SWX:NOVN) completed the acquisition of Chinook Therapeutics, Inc. (NasdaqGS:KDNY) from a group of shareholders.

Novartis Ag Announces Positive Top-Line Results from the Phase Iii Remix-1 and Remix-2 Studies Evaluating Remibrutinib 25 Mg B.I.D

Novartis AG (SWX:NOVN) acquired DTx Pharma, Inc. for $1 billion.

US FDA Approves Expanded Indication for Novartis Leqvio® (Inclisiran) to Include Treatment of Adults with High LDL-C and Who Are at Increased Risk of Heart Disease

Bausch + Lomb Corporation (NYSE:BLCO) signed an agreement to acquire ophthalmology assets from Novartis AG (SWX:NOVN) for $2.5 billion.

Revenue & Expenses BreakdownBeta

Earnings and Revenue History

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Return on Equity

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Revenue & Expenses Breakdown
Beta